Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease

NCT02021110 | Completed Phase 2 DMC

• 1 other identifier: PLD 11-01
• Study Type: interventional
• Target: 34
• Locations: 2 countries
• Sites: 3

Brief Summary

Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by \>20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic kidney disease (ADPKD), or isolated in the absence of renal cysts as autosomal dominant polycystic liver disease (ADPLD or PCLD). PLD patients are confronted with symptoms caused by the mass effect of their polycystic liver every day for the rest of their life. There is no standard therapeutic option for symptomatic PLD patients. Current options are fairly invasive or their efficacy is only moderate. Preliminary data in our research lab have shown that ursodeoxycholic acid (UDCA) inhibited the proliferation of polycystic human cholangiocytes in vitro through the normalization of the intracellular calcium levels in cystic cholangiocytes. The investigators also found that daily oral administration of UDCA for 5 months to polycystic kidney disease (PCK) rats, an animal model of ARPKD that spontaneously develops hepato-renal cystogenesis, resulted in inhibition of hepatic cystogenesis. The investigators hypothesize that UDCA is an effective therapeutic tool in reducing liver volume in PLD. Objective: First, to demonstrate whether UDCA-therapy is effective in reducing total liver volume in PLD patients. Second, the investigators want to assess if UDCA modifies quality of life. Finally, the investigators want to assess safety and tolerability. Study design: International, multicenter, randomized, controlled trial Study population: 34 subjects (18 ≤age ≤ 80 years) suffering from symptomatic polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts on CT-scan and liver volume of ≥ 2500. Symptomatic is defined as Eastern Cooperative Oncology Group- Performance Score (ECOG-PS) ≥ 1 and having at least three out of ten PLD symptoms. Intervention: The patients will be randomized (1:1) into two groups. One group of patients will receive 15-20mg/kg/day UDCA for 24 weeks. The other group will receive standard care. Main study endpoint: Proportional change of total liver volume in UDCA treated patients versus non treated patients, as assessed by CT at baseline and 6 months.

Conditions

Polycystic Liver Disease; Polycystic Kidney, Autosomal Dominant

Outcome Measures

Primary Outcomes (1)

• Effect of UDCA on total liver volume

  Proportional change of total liver volume in UDCA treated patients versus non treated patients, as assessed by CT at baseline and week 24

  Baseline to week 24

Secondary Outcomes (5)

• Effect of UDCA-therapy on absolute total liver volume

  Baseline to week 24

• Effect of UDCA on gastro-intestinal symptoms measured by a GI-questionnaire

  Baseline to week 24

• Effect of UDCA on health related quality of life as measured by Study Form -36

  Baseline to week 24

• Proportion of patients with any reduction in total liver volume after 24 weeks

  Baseline to week 24

• Effect of UDCA on absolute total kidney volume

  Baseline to week 24

Other Outcomes (1)

• Adverse events as a measure of tolerability and safety of UDCA

  Baseline to week 24

Study Arms (2)

Control group

NO INTERVENTION

This group will receive standard care (no treatment)

Ursodeoxycholic Acid

EXPERIMENTAL

The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks

Drug: Ursodeoxycholic Acid

Interventions

Ursodeoxycholic Acid DRUG

The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks

Also known as: Ursochol

Ursodeoxycholic Acid

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≤ age ≤ 80 years
• Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
• Total liver volume ≥ 2500 mL
• Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
• Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.

You may not qualify if:

• Use of oral anticonceptives or estrogen supplementation
• Use of UDCA in 3 months before baseline
• Females who are pregnant or breast-feeding or patients of reproductive potential not employing an effective method of birth control.
• Intervention (aspiration or surgical intervention) within six months before baseline
• Treatment with somatostatin analogues within six months before baseline
• Renal dysfunction (MDRD-Glomerular filtration rate\< 30 ml/min/1.73m2)
• Patients with a kidney transplant
• Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase deficiency or glucose-galactose malabsorption
• Acute cholecystitis or frequent biliary colic attacks
• Acute stomach or duodenal ulcers
• Inflammation of small intestine or colon
• Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
• Enrolment in another clinical trial of an investigational agent while participating in this study
• History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
• Mental illness that interferes with the patient ability to comply with the protocol

Sponsors & Collaborators

• Radboud University Medical Center: lead
• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): collaborator

Study Sites (3)

Radboud University Medical Centre Nijmegen

Nijmegen, Gelderland, Netherlands

Location

Academic Medical Centre Amsterdam

Amsterdam, Netherlands

Location

Donostia University Hospital

Donostia / San Sebastian, Spain

Location

Related Publications (1)

• D'Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK, Brunenberg EJ, Beuers U, Banales JM, Drenth JP. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol. 2016 Sep;65(3):601-7. doi: 10.1016/j.jhep.2016.05.009. Epub 2016 May 17.

  PMID: 27212247 DERIVED

MeSH Terms

Conditions

Polycystic liver disease; Polycystic Kidney, Autosomal Dominant

Interventions

Ursodeoxycholic Acid

Condition Hierarchy (Ancestors)

Polycystic Kidney Diseases; Kidney Diseases, Cystic; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ciliopathies; Genetic Diseases, Inborn

Intervention Hierarchy (Ancestors)

Deoxycholic Acid; Cholic Acids; Bile Acids and Salts; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Cholanes

Study Officials

• Joost PH Drenth, dr.

  Radboud University Medical Centre Nijmegen, the Netherlands

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 12, 2013
• First Posted: December 27, 2013
• Study Start: December 1, 2013
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2015
• Last Updated: September 23, 2021

Record last verified: 2016-04

Locations

ES (1); NL (2)